File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis
  • Basic View
  • Metadata View
  • XML View
TitleHigh expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis
 
AuthorsXiao, XS1
Cai, MY1
Chen, JW1
Guan, XY1
Kung, HF1 2
Zeng, YX1
Xie, D1
 
KeywordsBreast Cancer
P300
Prognosis
Tumor Recurrence
 
Issue Date2011
 
PublisherChina Anti-Cancer Association. The Journal's web site is located at http://zgazyj.periodicals.net.cn/
 
CitationChinese Journal Of Cancer Research, 2011, v. 23 n. 3, p. 201-207 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s11670-011-0201-5
 
AbstractObjective: Transcriptional coactivator p300 has been shown to play a variety of roles in the transcription process and mutation of p300 has been found in certain types of human cancers. However, the expression dynamics of p300 in breast cancer (BC) and its effect on BC patients' prognosis are poorly understood. Methods: In the present study, the methods of tissue microarray and immunohistochemistry (IHC) were used to investigate the protein expression of p300 in BCs. Receiver operating characteristic (ROC) curve analysis, Spearman's rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were utilized to analyze the data. Results: Based on the ROC curve analysis, the cutoff value for p300 high expression was defined when the H score for p300 was more than 105. High expression of p300 could be observed in 105/193 (54.4%) of BCs, in 6/25 (24.0%) of non-malignant breast tissues, respectively (P=0.004). Further correlation analysis showed that high expression of p300 was positively correlated with higher histological grade, advanced clinical stage and tumor recurrence (P<0.05). In univariate survival analysis, a significant association between high expression of p300 and shortened patients' survival and poor progression-free survival was found (P<0.05). Importantly, p300 expression was evaluated as an independent prognostic factor in multivariate analysis (P<0.05). Conclusion: Our findings provide a basis for the concept that high expression of p300 in BC may be important in the acquisition of a recurrence phenotype, suggesting that p300 high expression, as examined by IHC, is an independent biomarker for poor prognosis of patients with BC. © 2011 Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg.
 
ISSN1000-9604
2013 Impact Factor: 0.932
2013 SCImago Journal Rankings: 0.231
 
DOIhttp://dx.doi.org/10.1007/s11670-011-0201-5
 
ISI Accession Number IDWOS:000297246600007
Funding AgencyGrant Number
National Natural Science Foundation of China30901709
National "973" Basic Research Program of China2010CB529400
2010CB912802
Funding Information:

This work was supported by a grant from the National Natural Science Foundation of China (No. 30901709), the National "973" Basic Research Program of China (No. 2010CB529400 and 2010CB912802).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorXiao, XS
 
dc.contributor.authorCai, MY
 
dc.contributor.authorChen, JW
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorKung, HF
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorXie, D
 
dc.date.accessioned2012-06-26T06:12:03Z
 
dc.date.available2012-06-26T06:12:03Z
 
dc.date.issued2011
 
dc.description.abstractObjective: Transcriptional coactivator p300 has been shown to play a variety of roles in the transcription process and mutation of p300 has been found in certain types of human cancers. However, the expression dynamics of p300 in breast cancer (BC) and its effect on BC patients' prognosis are poorly understood. Methods: In the present study, the methods of tissue microarray and immunohistochemistry (IHC) were used to investigate the protein expression of p300 in BCs. Receiver operating characteristic (ROC) curve analysis, Spearman's rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were utilized to analyze the data. Results: Based on the ROC curve analysis, the cutoff value for p300 high expression was defined when the H score for p300 was more than 105. High expression of p300 could be observed in 105/193 (54.4%) of BCs, in 6/25 (24.0%) of non-malignant breast tissues, respectively (P=0.004). Further correlation analysis showed that high expression of p300 was positively correlated with higher histological grade, advanced clinical stage and tumor recurrence (P<0.05). In univariate survival analysis, a significant association between high expression of p300 and shortened patients' survival and poor progression-free survival was found (P<0.05). Importantly, p300 expression was evaluated as an independent prognostic factor in multivariate analysis (P<0.05). Conclusion: Our findings provide a basis for the concept that high expression of p300 in BC may be important in the acquisition of a recurrence phenotype, suggesting that p300 high expression, as examined by IHC, is an independent biomarker for poor prognosis of patients with BC. © 2011 Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationChinese Journal Of Cancer Research, 2011, v. 23 n. 3, p. 201-207 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s11670-011-0201-5
 
dc.identifier.citeulike9763566
 
dc.identifier.doihttp://dx.doi.org/10.1007/s11670-011-0201-5
 
dc.identifier.epage207
 
dc.identifier.isiWOS:000297246600007
Funding AgencyGrant Number
National Natural Science Foundation of China30901709
National "973" Basic Research Program of China2010CB529400
2010CB912802
Funding Information:

This work was supported by a grant from the National Natural Science Foundation of China (No. 30901709), the National "973" Basic Research Program of China (No. 2010CB529400 and 2010CB912802).

 
dc.identifier.issn1000-9604
2013 Impact Factor: 0.932
2013 SCImago Journal Rankings: 0.231
 
dc.identifier.issue3
 
dc.identifier.scopuseid_2-s2.0-80052865221
 
dc.identifier.spage201
 
dc.identifier.urihttp://hdl.handle.net/10722/150839
 
dc.identifier.volume23
 
dc.languageeng
 
dc.publisherChina Anti-Cancer Association. The Journal's web site is located at http://zgazyj.periodicals.net.cn/
 
dc.publisher.placeChina
 
dc.relation.ispartofChinese Journal of Cancer Research
 
dc.relation.referencesReferences in Scopus
 
dc.subjectBreast Cancer
 
dc.subjectP300
 
dc.subjectPrognosis
 
dc.subjectTumor Recurrence
 
dc.titleHigh expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Xiao, XS</contributor.author>
<contributor.author>Cai, MY</contributor.author>
<contributor.author>Chen, JW</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2012-06-26T06:12:03Z</date.accessioned>
<date.available>2012-06-26T06:12:03Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Chinese Journal Of Cancer Research, 2011, v. 23 n. 3, p. 201-207</identifier.citation>
<identifier.issn>1000-9604</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/150839</identifier.uri>
<description.abstract>Objective: Transcriptional coactivator p300 has been shown to play a variety of roles in the transcription process and mutation of p300 has been found in certain types of human cancers. However, the expression dynamics of p300 in breast cancer (BC) and its effect on BC patients&apos; prognosis are poorly understood. Methods: In the present study, the methods of tissue microarray and immunohistochemistry (IHC) were used to investigate the protein expression of p300 in BCs. Receiver operating characteristic (ROC) curve analysis, Spearman&apos;s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were utilized to analyze the data. Results: Based on the ROC curve analysis, the cutoff value for p300 high expression was defined when the H score for p300 was more than 105. High expression of p300 could be observed in 105/193 (54.4%) of BCs, in 6/25 (24.0%) of non-malignant breast tissues, respectively (P=0.004). Further correlation analysis showed that high expression of p300 was positively correlated with higher histological grade, advanced clinical stage and tumor recurrence (P&lt;0.05). In univariate survival analysis, a significant association between high expression of p300 and shortened patients&apos; survival and poor progression-free survival was found (P&lt;0.05). Importantly, p300 expression was evaluated as an independent prognostic factor in multivariate analysis (P&lt;0.05). Conclusion: Our findings provide a basis for the concept that high expression of p300 in BC may be important in the acquisition of a recurrence phenotype, suggesting that p300 high expression, as examined by IHC, is an independent biomarker for poor prognosis of patients with BC. &#169; 2011 Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg.</description.abstract>
<language>eng</language>
<publisher>China Anti-Cancer Association. The Journal&apos;s web site is located at http://zgazyj.periodicals.net.cn/</publisher>
<relation.ispartof>Chinese Journal of Cancer Research</relation.ispartof>
<subject>Breast Cancer</subject>
<subject>P300</subject>
<subject>Prognosis</subject>
<subject>Tumor Recurrence</subject>
<title>High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s11670-011-0201-5</identifier.doi>
<identifier.scopus>eid_2-s2.0-80052865221</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80052865221&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>23</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>201</identifier.spage>
<identifier.epage>207</identifier.epage>
<identifier.isi>WOS:000297246600007</identifier.isi>
<publisher.place>China</publisher.place>
<identifier.citeulike>9763566</identifier.citeulike>
</item>
Author Affiliations
  1. Sun Yat-Sen University Cancer Center
  2. Chinese University of Hong Kong